Efgartigimod Alfa-fcab (Vyvgart); Efgartigimod Alfa-fcab and Hyaluronidase-qvfc (Vyvgart Hytrulo)
Customize your policy alerts
Sign up for blue cross blue shield - tennessee Policy ID_CHS_51022026a_1026 alerts
Get alerted when Policy ID_CHS_51022026a_1026 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and continuation coverage for Vyvgart and Vyvgart Hytrulo in adults with generalized myasthenia gravis, and for Vyvgart Hytrulo in adults with chronic inflammatory demyelinating polyneuropathy. Coverage requires applicable clinical criteria, documentation, and prescribing by or consultation with a neurologist.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.